Description: Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio's proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines. Nuvation Bio has offices in New York and San Francisco.
Home Page: www.nuvationbio.com
NUVB Technical Analysis
1500 Broadway
New York,
NY
10036
United States
Phone:
332 208 6102
Officers
| Name | Title |
|---|---|
| Dr. David T. Hung M.D. | Founder, Pres, CEO & Director |
| Ms. Jennifer A. Fox | CFO & Sec. |
| Dr. David C. Hanley Ph.D. | Chief Technical Operations Officer |
| Dr. Gary Hattersley Ph.D. | Chief Scientific Officer |
| Ms. Stacy Markel | Chief People Officer |
| Ms. Kerry A. Wentworth | Chief Regulatory Officer |
| Dr. David Liu M.D., Ph.D. | Chief Medical Officer |
Exchange: NYSE
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.6278 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2020-08-24 |
| Fiscal Year End: | December |
| Full Time Employees: | 54 |